![]() ![]() This press release contains information that includes or is based on "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. ![]() More information, including this and past press releases of Endo Pharmaceuticals Holdings Inc., is available at Forward-Looking Statements subsidiary, the company is engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Through its wholly owned Endo Pharmaceuticals Inc. is a specialty pharmaceutical company with market leadership in pain management. Holveck received a BS in education/science from West Chester University.Įndo Pharmaceuticals Holdings Inc. He is a former board member of the Pharmaceutical Research and Manufacturing Association (PhRMA) and the Biotechnology Industry Organization. Holveck is a member of the Board of Trustees for The Fund for West Chester University, the Board of Directors of the Eastern Technology Council and Cleveland Clinic's Industrial Advisory Board. Prior to joining Centocor, he had held positions at General Electric Company, Corning Glass Works and Abbott Laboratories. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. in 1983 and progressed through various executive positions. ![]() Holveck was Chief Executive Officer of Centocor, Inc. by Johnson & Johnson, and assumed his current position in 2004. Holveck, 62, joined Johnson & Johnson as a company Group Chairman in 1999, following the acquisition of Centocor, Inc. Our entire organization will benefit from Dave's experience." Dave will be a tremendous asset to our company and I am eager to begin working with him. ![]() Wysenski, Chief Operating Officer of Endo Pharmaceuticals, said: "I am delighted to welcome Dave Holveck to Endo Pharmaceuticals. I appreciate the confidence of the Board of Directors and look forward to working with my new colleagues on the management team and all the employees of Endo to deliver important pharmaceutical products to patients and build value for our shareholders." Endo has an outstanding market position in the pain management sector and a wide range of attractive growth opportunities. Holveck said: "I am honored to lead Endo Pharmaceuticals, a company that I have known and respected for many years. He has a unique combination of deep experience and an entrepreneurial spirit that can lead Endo to the next level." He has a track record of strong performance, successfully managing product development, building great organizations and creating value. Throughout his career at Centocor and Johnson & Johnson, he has demonstrated exceptional vision and leadership. Roger Kimmel, Chairman of the Board of Directors of Endo, said: "Dave Holveck is the ideal executive to lead Endo Pharmaceuticals as it pursues growth opportunities and enhanced shareholder value. He was formerly President and Chief Executive Officer of Centocor, Inc., until the acquisition of that company by Johnson & Johnson in 1999. Holveck was most recently President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson (NYSE: JNJ). Holveck has been named President, Chief Executive Officer and a Director of the company, effective April 1, 2008. Holveck President and Chief Executive OfficerĬHADDS FORD, PA, - Endo Pharmaceuticals Holdings today announced that David P. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |